drugset / Trial / NCT06319313
Efficacy and Safety of JMT101 Combined Wth Docetaxel / HB1801 in Patients With Squamous Cell Non-Small Cell Lung Cancer
RandomizedParallel-groupOpen-labelTreatment
Summary
This study is a phase II/III, randomized, controlled, open-label, multi-center study with safety run-in to evaluate the efficacy and safety of JMT101 combined with docetaxel/ HB1801 in Patients with Squamous cell non-small cell lung cancer （sqNSCLC）.
Timeline
- Start
- 2024-05-01
- Primary completion
- 2026-07-01
- Completion
- 2027-12-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | 50 mg/m2, IV infusion once every 2 weeks (one treatment cycle is 4 weeks). Or 75 mg/m2, IV infusion once every 3 weeks. | Unknown | 50 mg/m2 | Intravenous |
| Subject | 50 mg/m2, IV infusion once every 2 weeks (one treatment cycle is 4 weeks). Or 75 mg/m2, IV infusion once every 3 weeks. | Unknown | 75 mg/m2 | Intravenous |
| Subject | 75 mg/m2, IV infusion once every 2 weeks (one treatment cycle is 4 weeks). Or 100 mg/m2, IV infusion once every 3 weeks. | Unknown | 75 mg/m2 | Intravenous |
| Subject | 75 mg/m2, IV infusion once every 2 weeks (one treatment cycle is 4 weeks). Or 100 mg/m2, IV infusion once every 3 weeks. | Unknown | 100 mg/m2 | Intravenous |
| Subject | BECOTATUG | Monoclonal antibody | 6 mg/kg | Intravenous |
| Subject | BECOTATUG | Monoclonal antibody | 9 mg/kg | Intravenous |